<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897037</url>
  </required_header>
  <id_info>
    <org_study_id>Bright2</org_study_id>
    <nct_id>NCT02897037</nct_id>
  </id_info>
  <brief_title>Bivalirudin in Acute Myocardial Infarction</brief_title>
  <official_title>Bivalirudin vs Heparin During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Salubris Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Salubris Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI
      patients with DES.

      This is a prospective, randomized, single-blind, active drug controlled multicenter clinical
      research and the study would enrolled a total of 380 AMI patients undergoing percutaneous
      coronary intervention (PCI) to one of two antithrombotic regimens: bivalirudin alone, or
      unfractionated heparin alone. All enrolled patients would be followed-up to 30 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single-blind, active drug controlled multicenter clinical
      research and the study would enrolled a total of 380 AMI patients undergoing percutaneous
      coronary intervention (PCI) to one of two antithrombotic regimens: bivalirudin alone, or
      unfractionated heparin alone. All enrolled patients would be followed-up to 30 days. The
      purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients
      with DES.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net Adverse Clinical Events</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of all cause death, reinfarction, urgent target vessel revascularization, stroke and any bleedings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of all cause death, reinfarction, target vessel revascularization or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any bleedings (BARC class)</measure>
    <time_frame>30 days</time_frame>
    <description>Including all BARC class (class 3-5)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT&lt;225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 IU/kg intravenous bolus. If ACT &lt;225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.</description>
    <arm_group_label>Bivalirudin</arm_group_label>
    <other_name>Taijianing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin</intervention_name>
    <description>heparin monotherapy</description>
    <arm_group_label>Heparin monotherapy</arm_group_label>
    <other_name>Gansu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 80 years old

          2. Planned emergency PCI for acute myocardial infarction (STEMI) Symptom onset within 12h
             for STEMI (or within 12-24 hrs for patients have unrelieved chest pain, continuous ST
             elevation or new developed LBBB)

          3. Provide written informed consent.

        Exclusion Criteria:

          1. Age &lt;18 or &gt;80 years.

          2. Any anticoagulant drugs were regularly used within 3 months.

          3. Any anticoagulant agents were used 48 h before randomization.

          4. Active bleeding or bleeding constitution, bleeding tendency, including the recent
             retina or vitreous hemorrhage (1 months), GI or urinary tract hemorrhage (3 months),
             cerebral hemorrhage (6 months) or cerebral infarction history (3 months), etc.

          5. Hemoglobin &lt; 90 g/L or platelet count &lt; 100 * 109 / L.

          6. Untreated or uncontrolled hypertension &gt; 180/110 mmHg.

          7. Elevated ALT level higher than three times of the normal upper limit;severe renal
             insufficiency (eGFR &lt; 30 mL/min / 1.73 m2).

          8. Heparin induced thrombocytopenia.

          9. Suspicious aortic dissection, pericarditis and subacute bacterial endocarditis.

         10. Known allergy to the study drugs and instruments (UFH, bivalirudin, aspirin and
             clopidogrel, stainless steel, contrast agents, etc.), or those allergic constitution.

         11. Pregnancy , lactation or plan to be pregnant.

         12. Known serious progressive diseases such as malignant tumor or prognosis of the
             patients with severe failure;the survival time &lt; 6 months.

         13. Unsuitable for PCI.

         14. Attended any clinical trial 1 month before randomised.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiangjing Long, Dr.</last_name>
    <phone>86-10-58696282</phone>
    <phone_ext>840</phone_ext>
    <email>longjianjing@salubris.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Hou, Dr.</last_name>
    <phone>86-10-58696282</phone>
    <phone_ext>821</phone_ext>
    <email>houyan@salubris.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiologyï¼ŒGeneral Hospital of Shenyang Military Region</name>
      <address>
        <city>Shanyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyang Liang, Dr.</last_name>
      <phone>86-13332457575</phone>
      <email>doctorliangzi@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Li</last_name>
      <email>doctorliyi@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>November 25, 2016</last_update_submitted>
  <last_update_submitted_qc>November 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bivalirudin</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>percutaneous transluminal coronary angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

